Advertisement

Drugs & Therapy Perspectives

, Volume 17, Issue 7, pp 1–4 | Cite as

Bexarotene offers new hope for patients with refractory cutaneous T cell lymphoma

New drugs and disease management
  • 11 Downloads

Keywords

Retinoid Fenofibrate Isotretinoin Topical Formulation Bexarotene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000 Jul–Aug; 1(4): 245–50PubMedCrossRefGoogle Scholar
  2. 2.
    Bengtson EM, Rigas JR. New oral chemotherapeutic agents for lung cancer. Drugs 1999; 58 Suppl. 3; 57–69PubMedCrossRefGoogle Scholar
  3. 3.
    Nagy L, Thomazy VA, Shipley GL, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15: 3540–51PubMedGoogle Scholar
  4. 4.
    Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146–55PubMedCrossRefGoogle Scholar
  5. 5.
    Duvic M, Martin A, Kim Y, et al. Phase II–III clinical trial of bexarotene capsules demonstrates efficacy and safety for patients with refractory or persistent early stage CTCL [abstract no. 231 & poster]. 58th Annual Meeting of the American Academy of Dermatology. 2000 Mar 10–15; San FranciscoGoogle Scholar
  6. 6.
    Heald P, Mehlmauer M, Martin A, et al. The benefits of topical bexarotene (Targretin®) in patients with refractory or persistent early stage CTCL [abstract no. 545]. J Invest Dermatol 2000 Apr; 114: 840Google Scholar
  7. 7.
    Kuzel T, Breneman D, Duvic M, et al. Phase I–II trial of Tagretin® gel in the topical treatment of patients with cutaneous T-cell lymphoma [abstract no. 532]. J Invest Dermatol 2000 Apr; 114: 839Google Scholar
  8. 8.
    Hymes K, Duvic M, Heald P, et al. Oral bexarotene benefits patients with refractory advanced stage CTCL [abstract no. 425 & poster]. 41st Annual Meeting and Exposition of the American Society of Hematology. 1997 Dec 3–7; New OrleansGoogle Scholar
  9. 9.
    Duvic M, Hymes K, Heald P, et al. Phase II–III clinical trial of bexarotene capsules in patients with refractory advanced stage CTCL demonstrates efficacy and safety [abstract no. 60 & poster]. 58th Annual Meeting of the American Academy of Dermatology. 2000 Mar 10–15; San FranciscoGoogle Scholar
  10. 10.
    Hymes KB, Washenik K, Duvic M, et al. Oral bexarotene in CTCL patients by TNM stage of disease [abstract no. 53]. 36th Annual Meeting of the American Society of Clinical Oncology. 2000 May 20–23; New Orleans, 16aGoogle Scholar
  11. 11.
    Hein NI, Howell SR, Ulm EH. Evaluation of the cytochrome P450 isozymes involved in the metabolism of Targretin™, and RXR-selective retinoid [abstract]. 7th ISSX 1996 Oct 20; 10: 364Google Scholar
  12. 12.
    Martin AG. Bexarotene: a viewpoint. Am J Clin Dermatol 2000 Jul–Aug; 1(4): 252CrossRefGoogle Scholar
  13. 13.
    Ligand Pharmaceuticals Incorporated. Package insert. Targretin® (bexarotene) gel 1%. Available from: URL: http://www.ligand.com [accessed 2001 Mar 8]
  14. 14.
    Ligand Pharmaceuticals Incorporated. Package insert. Targretin® (bexarotene) capsules, 75mg. Available from: URL: http://www.ligand.com [accessed 2001 Mar 8]
  15. 15.
    Rook AH, Lehrer MS, Junkins-Hopkins JM, et al. Bexarotene: a viewpoint. Am J Clin Dermatol 2000 Jul–Aug; 1(4): 251CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations